The current application claims a foreign priority to application number 103129255 filed on Aug. 25, 2014.
1. Field of the Invention
The present invention relates generally to the technology of separating active ingredients in placenta, and more particularly to a method which can separate estrogen, peptide and vitamins, trace elements and other functional ingredients in placenta.
2. Description of Related Art
As the source of nutrition for the fetus, placenta contains essential amino acids and pharmacologically active peptides, vitamins, minerals and various growth factors. According to research, its major functional ingredients include immunoglobulin, anti-aging peptides, rich lecithin, human brain phospholipids, lipopolysaccharides, a variety of vitamins and trace elements in addition to transfer factor, protein activity factor, collagen, and nucleic acid compounds. Therefore, placenta ingredients have the anti-aging, skin lightening, immunity improving and endocrine regulating functions. However, excessive use of estrogen, progesterone and other ingredients in placenta can cause cardiovascular diseases, cancer and other health problems.
Conventional methods of extraction and separation of the placenta peptide include the repeated freeze-thaw method, acid or alkaline hydrolysis, enzymatic method etc. For example, the disclosed US invention patent of US20130072466A1 proposes to use the mixed solvents of ethyl acetate, chloroform, ether, hexane and other organic solvents for the extraction of estrogen and other ingredients from placenta. The precipitation is then by adding alkaline substances in the extracted solution. Finally, the extracted substances are neutralized by acid solution. However, this process takes a long time and produces a large amount of acids, alkalis and organic solvents and wastes, resulting in the decomposition of functional ingredients and toxic residues. The Chinese patent of CN101837005B proposes to use alkali solution in the pretreatment of pig placenta and to hydrolyze the mixture by proteinase. The lipopolysaccharide and other functional ingredients in placenta are then precipitated by organic solvents. The US patent of US3041245 proposes to extract the albumin-containing active substance for skin care ingredients in mammalian placenta by using acidic solution with acetone organic solvent. The disclosed US invention patent US20130072466A1 proposes to use mixed organic solvents for the extraction of estrogen and other ingredients from placenta.
Regarding the above conventional extraction and separation methods, the processes are complicated and time-consuming with the addition of a large amount of acid solution, alkali solution, and organic solvents. The organic solvents may chemically react with the functional ingredients. During the solvent removal and condensation process after the extraction, the heating and vaporization of solvents may damage some of the functional ingredients and the solvents may residue in extracts or purified products. Therefore, such methods cannot easily, safely and efficiently separate and completely retain the functional ingredients in placenta including peptides, vitamins and trace elements.
The main purpose of this invention is to provide a method to extract estrogen and oil from placenta without the complicated process of removing, condensation and separation process by using organic solvents. Moreover, it is free from the safety concern of solvent residues. It is low in cost can effectively improve the taste and nutrition of placenta powder products. Therefore, the method is a very environmentally friendly, safe, and practical one.
To achieve the above purposes, the present invention is a method for the extraction of functional ingredients in placenta. The steps include: deodorizing and extraction: under predetermined conditions of temperature and pressure, the placenta powder is placed inside an extraction tank before adding the supercritical solvents to deodorize the fishy smell of placenta powder and to extract placenta powder oil; adsorption of estrogen: under the same operating conditions as described in the above, the deodorized and extracted placenta powder and the supercritical CO2/ethanol solvents are flown into an adsorption tank at the predetermined volumetric flow rate ratio to adsorb the placenta powder estrogen to get the estrogen-removed placenta extracts; separation: under the predetermined operating conditions of temperature and pressure, the supercritical solvents are separated by rapid decompression to get the functional ingredients of the placenta powder.
The method is elaborated on a preferred implementation of the present invention as well as drawings:
First, as shown in
The second step is the adsorption of estrogen 120: under the same operating conditions (pressure 2000-4000 psi, temperature 40-60° C.)., the deodorized and oil-removal placenta powder, the supercritical CO2/ethanol solvents at volumetric flow rate ratio of 15:1 is flown into the adsorption tank for 2-3 hours. The placenta powder estrogen will be absorbed by the adsorbents. The adsorption tank is a stainless steel tank of internal diameter at 60 mm and height at 450 mm filled with adsorbents such as silica gel, sephadex or resin.
The third step of the invention is separation 130: under the operating conditions of pressure 1000-1200 psi and temperature 40° C., the functional ingredients extracts from the placenta powder can be separated by rapidly pressure-decreased and collected at the bottom of the adsorption tank.
Under the different operating conditions (by changing pressure, temperature and volumetric flow rate ratio of solvents at the supercritical state), the following is the description of the methods analyze and quantify the samples of placenta powder, samples collected at the bottom of extraction tank and adsorption tank. The analysis of the samples are the following substances: (1) oil yield, (2) estrogen concentration, (3) adipose derived stem cells (ADSC) viability, (4) protein concentration, (5) protein electrophoresis, (6) peptide concentration.
The measurement of oil yield, represented by %, is to compute the quantity of oil collected at the bottom of the extraction tank to be compared with the quantity of the placenta powder placed in the extraction tank. The estrogen concentration is quantified by ELISA on progesterone and estriol. The estrogen rejection, represented by %, is to compute the estrogen concentration of the samples collected at the bottom of adsorption tank in comparison with the quantity of the placenta powder. The measurement of ADSC viability (%) of collecting the samples at the bottom of adsorption tank is analyzed and measured by cell flowmeter. The samples of protein concentration collected at the bottom of the adsorption tank, represented by mg/g dw, are measured by the Bradford reagent test. The samples collected at the bottom of the adsorption tank are also analyzed by SDS-PAGE protein gel electrophoresis, quantified and represented by mg/g dw. The samples of peptide concentration, represented by mg/g dw, is analyzed by HPLC quantitative analysis.
The experimental results can be divided into four parts: (1) oil yield optimal extraction conditions, (2) placenta estrogen optimal separation conditions, (3) selection of ADSC viability extraction conditions, (4) selection of extraction conditions for protein, peptide and active ingredients concentration.
The use of supercritical carbon dioxide, or supercritical carbon dioxide and ethanol as a solvent can result in high solubility and mass transfer rate. Moreover, low temperature, low viscosity and high density can promote the contact of the extracted functional ingredients and to speed up and selectively separate from the placenta powder functional ingredients such as estrogen, peptide and vitamins and trace elements. Therefore, the preparation method of the patent can avoid conventional shortcomings of using large amounts of organic solvents for the hydrolysis of estrogen component structures by using acid, alkali and enzyme solutions.
In addition, to compare the difference between the effect of the present invention and conventional dialysis extraction techniques, following experiments are conducted: (1) after physiological saline solution of 20 times the mass of the placenta powder is added for homogenization, the dialysis tube rejecting molecules of molecular weight of 14,000 is used for dialysis in RO water of five times homogenized solution for six hours to get the extraction samples; (2) by applying the proposed method to analyze the following physical properties of the extraction solutions obtained by using the two processing methods: (1) color, (2) fishy smell, (3) estrogen concentration, (4) ADSC viability, (5) protein concentration, (6) peptide concentration. The changes in color are measured by the Japan-made Denshoku Σ90 colorimeter and represented by Hunter L, a, b value. The fishy smell is measured by professionals and scored by 0 to 10 points. 10 points indicate the most acceptable sample and 0 point indicates the unacceptable sample.
The analysis of the experimental data results are as shown in Table 1. Table 1 suggests that the L value of the extracted sample by the proposed method is close to 94 as comparison of the placenta powder samples color L value 47. Hunter L can be represented by values ranging from 0 to 100. When the value is closer to 100, it means the degree of transparency and clarity is higher. When the Hunter a or b value is higher, it suggests that the color red or yellow concentration is higher, respectively. The placenta powder samples processed by dialysis are in dark yellow turbid state. Therefore, the placenta samples processed by the conventional dialysis techniques are unacceptable in appearance, color and clarity. The samples prepared by using the present method have no fishy smell, no estrogen and clear appearance. As shown in Table 1, the samples prepared by the present method have high protein content and peptide concentration as well as ADSC viability.
The present invention of the method for the separation placenta functional ingredients uses non-toxic solvents at the supercritical state coupled with physical deodorizing and extraction, adsorption and separation. Due to its high solubility, low viscosity and high mass transfer efficiency, the solvents at the supercritical state can speed up and selectively separate the functional ingredients such as estrogen, peptide, vitamins and trace elements from placenta powder without safety concerns of solvent residues. The CO2 solvent at the supercritical state is an environmentally friendly and safe, and can be recycled and reused. Comparing to the conventional techniques of using a large amount of acid, alkali, enzyme solutions or organic solvents has the shortcoming of safety concern of residual solvents; the present invention is clearly progressive and has great practical value.
Number | Date | Country | Kind |
---|---|---|---|
103129255 | Aug 2014 | TW | national |